Introduction
============

SSc is a connective tissue disease characterized by fibrosis, together with activation and dysfunction of the immune system and endothelium. Endothelial injury is thought to be central to the pathogenesis of this condition \[[@kes068-B1]\]. Von Willebrand factor (vWF), a circulating glycoprotein synthesized by endothelial cells and megakaryocytes, acts as a carrier protein for the coagulation factor, factor VIII. It promotes adhesion of platelets to the subendothelium following vascular injury and has been validated as a marker of endothelial injury \[[@kes068-B2]\]. In previous small-scale studies, plasma vWF has been reported to be increased in SSc and potentially correlates with disease severity \[[@kes068-B3], [@kes068-B4]\]. No studies have previously examined the utility of vWF as a predictor of future disease manifestations.

Since the successful introduction of angiotensin-converting enzyme (ACE) inhibitors for the treatment of SSc renal crisis, pulmonary problems such as fibrosis and PAH are now the most serious complications \[[@kes068-B5]\]. Pulmonary artery hypertension (PAH) is more common in lcSSc associated with ACAs and can occur after the patient has suffered from the disease for many years. The morbidity and mortality from this complication is significant \[[@kes068-B6]\].

Recently, a number of treatments have become available that can improve the prognosis in established PAH \[[@kes068-B7]\]. There is now an imperative to determine, as early as possible, when pulmonary hypertension is developing \[[@kes068-B8]\] as an essential prerequisite for clinical trials to determine the impact of early intervention on outcome.

The QUINs randomized placebo-controlled trial \[Prevention of Vascular Damage in Scleroderma with Angiotensin-Converting Enzyme (ACE) Inhibition\] was set up to investigate the potential utility of quinapril in preventing digital ulcers in a large cohort of patients with lcSSc. We undertook this substudy to investigate the utility of vWF as a biomarker in this condition, measuring the vWF antigen at 0 and 3 years together with a range of clinical parameters at 12 weekly or annual intervals over the 3 years.

Methods
=======

Patients
--------

Two hundred and thirteen patients from 20 different centres across England and Wales with lcSSc \[[@kes068-B9]\] were recruited as part of the QUINs study. Approval for the study was gained from the Multicentre Research Ethics Committee (MREC Wales 00/09/19), and all centres gained local ethics committee approval. Patients gave written informed consent according to the Declaration of Helsinki.

vWF: antigen measurements
-------------------------

The vWF antigen (vWF:Ag) was measured at a single central lab (Aintree University Hospital) in sera of patients at baseline; follow-up measurements were taken after at least 2 years and no more than 3 years. vWF:Ag was measured using the STA Liatest Immuno-Turbidimetric assay. The detection threshold for the assay is 2%. The intra-assay reproducibility for the assay is 1.9--2.7% \[coefficient of variance (CV)\]. The inter-assay reproducibility of the assay is 2.9--4.5% (CV). The assay correlates well with ELISA procedures (*r* = 0.982).

Clinical measurements
---------------------

### 12 weekly measurements

Measurements included Rodnan skin score, digital ulcers, frequency and severity of RP on a visual analogue scale (VAS), a composite measurement of disease extent and severity using the Medsger score \[[@kes068-B10]\].

Annual measurements
-------------------

The estimated glomerular filtration rate (eGFR), 24-h urinary protein excretion, %DL~CO~, %FVC and %KCO were measured. Pulmonary artery pressure (PAP) was measured by an experienced operator at each site using echocardiography at baseline and at 3 years. PAP was taken to be the tricuspid gradient (mmHg) plus an estimate of right atrial pressure (10 mmHg).

Statistics
----------

Regression models were fitted to predict values recorded at 3 monthly or yearly intervals from the baseline value of the variable, treatment (placebo or quinapril) and the baseline vWF:Ag value. vWF:Ag levels correlated weakly with age (correlation coefficient = 0.168, *P* = 0.018) so all regression models were adjusted for age at the baseline visit. Robust Huber--White standard errors of the regression coefficients were used to take account of the observed correlations between repeated assessments of the same patient. High estimated PAP was analysed as a binary variable (yes/no) due to the way that the data were recorded during the study, i.e. PAP values were not quantified in 126 out of 323 patients with normal PAP \<30 mmHg. A logistic regression model was applied to binarized PAP. No adjustments were made for multiple comparisons.

Results
=======

vWF levels at follow-up visits did not differ significantly (*P* = 0.42) between the two randomized treatment groups (placebo *vs* quinapril) after adjusting for baseline vWF and age.

Relationships with vWF at baseline
----------------------------------

There is no significant relationship between baseline vWF:Ag and baseline values of concurrent/recent ulcers, Raynaud's attack frequency VAS score, Raynaud's severity VAS score or skin score. However, there was a significant relationship between baseline vWF:Ag and the Medsger score (a composite measurement of disease severity) (*β* = 0.0087, 95% CI 0.0025, 0.0149, *P* = 0.006). There was a significant relationship between baseline vWF:Ag and baseline urinary protein excretion (*β* = 0.0005, 95% CI 0.003, 0.0007, *P* \< 0.001) and baseline eGFR (*β* = 0.034, 95% CI 0.007, 0.060, *P* = 0.02).

There was a significant relationship between baseline vWF:Ag and baseline %FVC (*β* = −0.076, 95% CI − 0.119, −0.033, *P* = 0.001), %DL~CO~ (*β* = −0.079, 95% CI −0.119, −0.039, *P* \< 0.001) and with baseline PAP of \>30 mmHg (odds ratio = 0.998, 95% CI 0.977, 0.9998, *P* = 0.05) but not with baseline PAP of \>40 mmHg (*n* = 8) (odds ratio = 0.996, 95% CI 0.978, 1.015, *P* = 0.71).

vWF:Ag as a predictor of future outcomes
----------------------------------------

Two alternative definitions for raised PAP were explored: PAP \> 30 mmHg and PAP \> 40 mmHg. Logistic regression models to predict high PAP values during the follow-up from high baseline PAP, randomized treatment during the trial (quinapril or placebo) and baseline vWF:Ag indicate that baseline vWF:Ag is a predictor of PAP \> 40 mmHg (*P* = 0.001) and approached significance for prediction of PAP \> 30 mmHg (*P* = 0.11) ([Fig. 1](#kes068-F1){ref-type="fig"}). In regression models, baseline vWF:Ag was not a significant predictor of outcome for Raynaud's frequency, Raynaud's severity, new ulcer formation or skin score or any of the other clinical outcomes recorded during the follow-up ([Table 1](#kes068-T1){ref-type="table"}). F[ig]{.smallcaps}. 1Dot plot illustrating the relationship between baseline vWF:Ag and estimated PAP \>30 mmHg and 40 mmHg at 3 years (or the end of the study). T[able 1]{.smallcaps}Regression coefficients predicting outcome from baseline vWF:Ag, adjusted for baseline valuesOutcomeBaseline vWf:Ag regression coefficient[^a^](#kes068-TF1){ref-type="table-fn"}Odds ratio95% CI*P*-valuePAP \>30 mmHg^b^1.0070.998, 1.0170.11PAP \>40 mmHg^b^1.0221.009, 1.0350.001Number of new or recent digital ulcers0.0009−0.0003, 0.00210.15Raynaud's attack frequency VAS−0.0185−0.0651, 0.02820.44Raynaud's disease severity VAS−0.0192−0.0627, 0.02430.39Modified Rodnan skin score0.0025−0.0035, 0.00860.42Percentage of expected FVC−0.0150−0.0410, 0.01110.26Percentage of expected DL~CO~−0.0099−0.0356, 0.01590.45Percentage of expected KCO−0.0102−0.0367, 0.01620.45eGFR0.0006−0.0200, 0.02110.96Urinary protein, g/24 h0.0002−0.0002, 0.00070.30Medsger disease severity score0.0009−0.0043, 0.00600.75[^2]

Discussion
==========

This study, involving a large, well-characterized cohort of patients, was suitably placed to explore the utility of vWF:Ag as a biomarker in lcSSc. Previous smaller studies have suggested that plasma vWF:Ag may be raised in SSc compared with healthy controls and reflect disease severity \[[@kes068-B3], [@kes068-B4]\]. This study seems to confirm the latter, as vWF:Ag levels were related to the Medsger disease score that reflects the overall disease extent and severity. The relationship, however, is weak, and this may reflect the underlying problems in using vWF as a biomarker: levels are highly variable in the normal population and may be altered by factors such as exercise and ABO blood group \[[@kes068-B11]\]. A recent study in a small group of patients with SSc has suggested that vWF propeptide may be more useful as a marker of disease activity, but this assay was not available at the time this study commenced \[[@kes068-B12]\].

In this study we examined in particular the relationships with disease manifestations presumed to be directly a consequence of endothelial injury and dysfunction: number of ulcers, Raynaud's severity and attack frequency, urinary protein excretion and raised PAP. It is interesting to note that baseline vWF did correlate with urinary protein excretion and PAP. vWF did not correlate with Raynaud's severity and frequency, and this is likely to be due to the subjective and imprecise nature of these assessments. Of note, the average vWF:Ag levels decreased (mean change 15.9, 95% CI 5.8, 26.0, *P* = 0.002) over the 3 years of the study. This may reflect a decrease in endothelial injury over time, in keeping with the observations that inflammation, the presumed stimulus for endothelial injury, is greatest earlier in the disease.

Strikingly, we have identified the utility of baseline vWF:Ag to predict the future development of raised PAP. Previous studies have shown that vWF:Ag levels are elevated in patients with concurrent primary PAH and that levels are responsive to treatment \[[@kes068-B13], [@kes068-B14]\]. This suggests that endothelial injury does play a significant role in this condition.

This study is the first to report, importantly, that an increase in vWF is predictive of the future development of elevated PAP in patients with lcSSc. This may allow patients at risk of developing this life-threatening manifestation of the disease to be identified early. Of note, treatment with pravastatin significantly lowered vWF:Ag levels in patients with SSc. This was presumed to reflect a protective effect on the vascular endothelium \[[@kes068-B15]\]. It may be that prophylactic treatment of patients with raised vWF:Ag may reduce the risk of developing PAH, though this hypothesis remains to be tested. Statin use was not routinely recorded in our population.

Although echocardiography has its limitations in the assessment of PAP, it has been validated as an appropriate screening tool \[[@kes068-B16]\]. Three patients in this study had a right heart catheter to establish a more accurate assessment of PAP. Each had confirmed PAH and all three patients had very high levels of vWF:Ag at baseline: 201, 253 and 259% normal pooled plasma.
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[^1]: \*See [supplementary data](http://rheumatology.oxfordjournals.org/cgi/content/full/kes068/DC1), available at *Rheumatology* Online, for members of the QUINs Trial Study Group.

[^2]: ^a^Regression coefficients indicate the change in outcome per unit increase in vWFconcentration. Each regression coefficient is adjusted for age, randomized treatment (quinapril or placebo) and the baseline value of the outcome variable. Robust Huber--White sandwich estimators of the standard errors of the regression coefficients were used to construct the 95% CI, which take account of the observed correlation between repeated assessments on the same patient. ^b^Odds ratio from a logistic regression model.
